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Abstract: The memory-guided saccade task requires the remembrance of a peripheral target location,
whilst inhibiting the urge to make a saccade ahead of an auditory cue. The literature has explored
the endophenotypic deficits associated with differences in target laterality, but less is known about
target amplitude. The data presented came from Crawford et al. (1995), employing a memory-guided
saccade task among neuroleptically medicated and non-medicated patients with schizophrenia
(n = 31, n = 12), neuroleptically medicated and non-medicated bipolar affective disorder (n = 12,
n = 17), and neurotypical controls (n = 30). The current analyses explore the relationships between
memory-guided saccades toward targets with different eccentricities (7.5◦ and 15◦), the discernible
behaviour exhibited amongst diagnostic groups, and cohorts distinguished based on psychotic
symptomatology. Saccade gain control and final eye position were reduced among medicated-
schizophrenia patients. These metrics were reduced further among targets with greater amplitudes
(15◦), indicating greater deficit. The medicated cohort exhibited reduced gain control and final
eye positions in both amplitudes compared to the non-medicated cohort, with deficits markedly
observed for the furthest targets. No group differences in symptomatology (positive and negative)
were reported, however, a greater deficit was observed toward the larger amplitude. This suggests
that within the memory-guided saccade paradigm, diagnostic classification is more prominent in
characterising disparities in saccade performance than symptomatology.
Keywords: memory-guided saccades; schizophrenia; bipolar disorder; positive symptoms; nega-
tive symptoms
1. Introduction
Research published over the past decade has highlighted and established an encour-
aging novel area of research which considers the oculomotor system as an effector system
for visual memory ([1], for review). Research exploring the expression of memory through
eye movements demonstrate how they are not simply a passive reflection of memory, but
rather play an active role in contributing to the formation and retrieval of information [2].
The memory-guided saccade task is a highly informative paradigm, which requires
remembering the location of a peripheral target, whilst inhibiting the urge to make a
saccade to that target ahead of an auditory cue. Typically, individuals would produce a
reflexive eye movement in response to a novel stimulus, but in the memory-guided saccade
paradigm they are asked to suppress and delay their saccade until the presentation of a
cue. Whilst suppressing this saccade, fixation should be maintained at the centre of the
display while simultaneously encoding the spatial location of a peripheral target stimulus.
During the delay period before receiving the cue, cells in the superior colliculus respond to
the continued presence of the fixation stimulus [3,4], facilitating inhibition and maintaining
the spatial representation of the peripheral location. Upon receiving the cue, a volitional
saccade to the remembered target ensues. No visual information is provided on the location
of the previously presented peripheral target at the moment of saccade initiation. This
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paradigm, therefore, examines the inhibition of a reflexive action, the ability to generate
an internal representation of space (spatial working memory), and the inhibition of the
saccadic motor program during the memorisation process. A major advantage of the
oculomotor system is that detailed neurophysiological and biochemical operations can be
explored using precise neuronal activity in equivalent or identical paradigms in animal
studies. In seminal work, Goldman-Rakic and colleagues [5] demonstrated that D1 neurons
in the dorsolateral pre-frontal cortex (DLPFC) played a critical role in memory-guided
oculomotor controls, and the generation of representations in working memory. Research
revealed that following inactivation of DLPFC with muscimol (a selective agonist for the
GABAA receptors), memory-guided saccades become hypometric and inaccurate in a
spatially specific manner [6]. While the DLPFC [5] and substantia nigra pars reticulata
(SNpr) [7] are implicated in the short-term memory buffer utilised during the memory-
guided saccade task, the parahippocampal cortex (PHC) may also be implicated in a
varied version of the memory-guided saccade task. Research has shown that accuracy of
memory-guided saccades, when memorisation delays are extended to between one and
twenty seconds, depends on the DLPFC [8], whilst the PHC is thought to be responsible for
accuracy when the delays are longer than twenty-seconds (and up to a few minutes) [8–11].
Saccadic eye movements are a ubiquitous form of information gathering (demon-
strated in primates) [12,13] and play a role in modulating ongoing neural activity in the
primate hippocampus [14–16]. However, Ryan et al. [1] highlight that there are no known
direct connections between hippocampal subfields and the oculomotor system. Thus,
they illustrated by examining whole-cortex connectivity in a model-based approach that
there is an extensive set of polysynaptic pathways mediating the exchange of information
between the oculomotor and memory systems [17]. Considering the functional dynamics
and recurrent interactions of the network involved in the hippocampal guidance of ocular
control, they highlight that neural activity in these areas, are important for the cognitive
and motoric control of eye movements [18]. Moreover, electrophysiological studies in
humans and primates [19,20], highlight that hippocampal memory representations are
used to guide saccades to behaviourally relevant locations [21]. With relevance to the
present research, visual exploration of novel, but not repeated stimuli result in a reset of
hippocampal theta oscillations [20], thus the consistency of this ability predicts the success
of novel memory encoding [22]. Given the role of the prefrontal cortex and schizophre-
nia pathology and treatment, the memory-guided saccade task employed, with small
memorisation periods and repeated stimulus presentation, would be expected to detect
neurocognitive impairment in patients with schizophrenia.
Previous research has explored the memory-guided saccade paradigm in relation to
the psychosis-continuum, highlighting a series of deficits distinguishing patients from
neurotypical controls ([23,24], for example). In memory-guided saccades, schizophrenia
patients have been shown to elicit increased latencies and/or reduced gain control and
final eye positions [24–31] as well as elevated disinhibition errors [23]. Decreased gain
control has been reported among psychosis patients and their relatives [25,26,30], as well as
increased latencies [24,27] among people with schizophrenia compared to controls. These
deficits have been shown to predate the onset of the disease [32,33]. This atypicality has
been replicated in psychosis patients [23,24,27,28,34] independent of medication status [28],
their full siblings [26], relatives [27,35], and those with high-schizotypy [36–38]; supporting
its candidacy as an oculomotor endophenotype.
All research cited thus far has largely overlooked the potential role of spatial location.
Given that targets closer to the fovea are more likely to capture attention due to the
cortical magnification factor and increased salience. If near targets require greater levels of
inhibition to avoid attentional capture, target eccentricity (how far away the remembered
target is from central fixation) may be expected to be a highly relevant factor. This may
also interact with symptomatology given that prefrontal impairment has been reliably
associated in schizophrenia (SZ) patients with predominantly negative symptoms [39–41].
There is evidence to suggest that differences may be observed when exploring these deficits
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in accordance with target eccentricity [42,43]. Existing research has demonstrated deficits
among patients with a family history of schizophrenia at smaller angles than patients
without a family history of this disease [42]. It is therefore relevant to explore these deficits
at different target eccentricities as this may provide higher specificity in detecting a marker
of vulnerability in schizophrenia [26]. The current work explores the dataset reported
by [23], to examine the effect target eccentricity (near vs. far targets) has on performance in
the memory-guided saccade task.
There are very few studies investigating the influence of target eccentricity in the
memory-guided saccade task, especially within psychosis patients. A key study, however,
is reported by Landgraf et al. [26] who explored memory-guided saccade metrics among
schizophrenia patients (n = 16), their family members (n = 19) and a control group (n = 18).
Data reported a reduction in errors from 46.2% at ‘small stimulus eccentricities’ (4◦, 6◦, 8◦)
to 5.6% at ‘large stimulus eccentricities’ (10◦, 12◦) among controls. This finding suggests
that controls are more susceptible to distractors that are closer to a central fixation point,
however, among the schizophrenia patients and their family members, no difference in
error production was reported. In alignment with the present research, Landgraf et al. [26]
explored primary saccade gain control and final eye position metrics, where schizophrenia
patients exhibited reduced performance when compared to their control counterparts
but overlooked the potential mediating effect of target eccentricity. A conclusion of this
study was that the memory-guided saccade paradigm provided a more specific way of
identifying saccadic abnormalities than other saccade paradigms, with involuntary errors
more prevalent in schizophrenia patients and their full-siblings, even at the largest target
amplitudes. They concluded that the paradigm could be utilised in identifying saccadic
abnormalities in psychoses. The present research therefore aims to expand on this analysis;
investigating whether primary saccade gain control and final eye position metrics are
affected by target eccentricity.
The present research also incorporates both schizophrenia and bipolar disorder (BD)
patients, to explore their comparative oculomotor responses to the memory-guided saccade
task. There is very little research exploring memory-guided saccades among bipolar disor-
der patients. Crawford et al. [23,44] illustrated no group differences (between schizophre-
nia, bipolar disorder, neurotics, and controls) in the latency metric, but trends towards
significant reductions in gain control and final eye position among schizophrenia patients.
In a systematic review, Carvalho et al. [45] did not report any literature exploring memory-
guided saccades among individuals with bipolar disorder. Moreover, the schizophrenia
cohort reported in the study carried out by Landgraf et al. [26] were all medicated; thus, the
present manuscript will therefore explore memory-guided saccades among medicated and
non-medicated individuals diagnosed with bipolar affective disorders, comparing their
oculomotor behaviours with those exhibited by medicated and non-medicated individuals
with schizophrenia.
A distinct limitation of the Landgraf et al. [26] paper is the lack of reference to symp-
tomatology. The symptomatology in the present research reflects on positive symptoms;
which describe an excess or distortion of normal mental function (for example, delusions,
hallucinations, disorganized behaviour), and negative symptoms, which refer to a diminu-
tion or absence of normal mental or psychological functions related to motivation and
interest (for example, anhedonia, asociality, and psychomotor poverty) or expression (for
example, blunted affect [46]). Existing research has highlighted significant associations
between patients with negative symptoms (as measured by either the SANS scale [47]
or the PANSS [48]) and greater suppression errors in the antisaccade task [28,49–51]. In
a small study (N = 21) Winograd-Gurvich et al. [52] explored the influence of negative
symptoms amongst a schizophrenia patient sample on a series of saccade tasks; one of
which included a memory-guided task. They describe how the high-negative symptom
group made a significantly greater percentage of errors than controls, with the memory-
guided saccade paradigm producing significantly longer latencies than other saccade tasks,
but there were no clear differences between the high and low negative were reported.
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No group differences were reported for gain control or final eye position measures; two
metrics thought to be important in psychotic saccade deficits [53]. However, this study
appears to be underpowered with only 10 and 11 participants per group. More recent
research has highlighted the existence of different relationships between the symptoms
of schizophrenia and saccade task performance. Obyedkov et al. [54] in a much larger
study (N = 156) highlighted that among schizophrenia patients and those at ultra-high
risk for psychosis, the negative symptoms but not positive or disorganized symptoms
were associated with atypical latencies in predictive and reflexive saccade tasks. This was
replicated by Smith and Crawford [53] who found significant hypometria and lower gain
control amongst those patients experiencing predominantly high-negative symptoms in
a predictive saccade task. Based on the existing evidence showing greater deficit among
those with predominantly negative traits, the current work explores whether this is true for
the deficits observed in the memory-guided saccade task. To our knowledge this is the first
study of the influence of symptomatology on the production of memory-guided saccades
amongst schizophrenia and bipolar disorder patients.
In this work, we will address the extent to which target eccentricity influences latency,
gain control, and final eye position measures in the memory-guided saccade task amongst
schizophrenia and bipolar affective patients, as well as control participants. We also aim to
address the influence medication may have on performance, and whether symptomatology
can distinguish between typical saccadic behaviour and deficit. Answering these questions
will further our understanding of essential features for the development of oculomotor
biomarkers, which can be utilised in the early diagnosis of psychosis.
2. Materials and Methods
2.1. Participant Selection
The dataset presented in this research came from the Crawford et al. [23,44] studies.
The participant groups consisted of medicated schizophrenia patients (M-SZ; n = 40;
21 male and 19 female; mean age ± SD = 40 ± 12 years, range = 22–61 years), non-
medicated schizophrenia patients (NM-SZ; n = 18; 17 male and 1 female; mean age ±
SD = 39 ± 13 years, range = 20–61 years), medicated bipolar affective disorder patients
(M-BD; n = 14; 7 male and 7 female; mean age ± SD = 44 ± 12 years, range = 20–60 years),
non-medicated bipolar affective disorder patients (NM-BD; n = 18; 12 male and 6 female;
mean age ± SD = 42 + 12 years, range = 20–60 years), and controls (CON; n = 31; 16 male
and 15 female; mean age ± SD = 39 ± 11 years, range = 25–57 years). All patients
were identified from the case notes of out-patients at the Royal London Hospital and
DSM-III-R criteria [55]. Controls were recruited from among all grades of hospital staff.
Informed consent was obtained from all the participants and the study was approved by
the Tower Hamlets Ethical Committee. The CONs and their immediate families lacked
any history of mental disease. Group matching, exclusion criteria, and further details
of the recruitment procedures and clinical assessments are reported in Supplementary
Materials (S1) and Crawford et al. [23,44]. Group means and standard deviations on all
clinical measures collected in Table 1. A one-way ANOVA showed no difference in age
between the diagnostic and control groups (F(4,118) = 0.546, p = 0.70).
To address the symptomatology of the participant groups, The Scale for the Assess-
ment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms
(SANS and SAPS) were employed. SANS measures negative symptoms on a 25 item,
6-point scale [47]. Items are listed under five domains of affective blunting, alogia, avo-
lition/apathy, anhedonia/asociality, and attention. SAPS measures positive symptoms
on a 34 item, 6-point scale [48]. Items are listed under hallucinations, delusions, bizarre
behavior, and positive formal thought disorder.
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Table 1. Clinical, psychiatric, and neuropsychological profile of medicated (M) and non-medicated (NM) schizophrenic
and bipolar patients, and control participants, as well as the current dosage of neuroleptic medication, expressed in
chlorpromazine equivalent units (group means and standard deviation).
Schizophrenia Patients Bipolar Disorder Patients Control
ParticipantsMedicated Non-Medicated Medicated Non-Medicated
Chlorprozamine equivalent
units 1637 (572) - 1186 (474) - -
Age (year) 39.9 (12.3) 39.4 (13.2) 43.6 (12.1) 42.1 (12.3) 38.5 (10.8)
Disease duration (year) 13.7 (10.7) 12.9 (14.8) 20.5 (11.6) 14.7 (13.6) -
Age of onset (year) 26.3 (8.9) 25.4 (10.6) 23.1 (8.9) 27.4 (12.2) -
Negative symptoms (SANS) 27.5 (17.1) 21.5 (19.7) 13.7 (17.6) 4.6 (6.8) 1.0 (1.9)
Positive symptoms (SAPS) 16.6 (21.7) 17.7 (17.8) 5.1 (9.2) 3.4 (6.6) 0.3 (0.2)
2.2. Measurement of Saccades
Apparatus set-up, procedure and the predictive saccade paradigm are reported in the
Supplementary Materials (S1) and reported in Crawford et al. [23,44].
For this memory-guided saccade task, each trial began with an illuminated central
LED. After 800 milliseconds (ms), a peripheral LED flashed on for 200 ms. The central
LED remained on, however, and the participant was instructed not to look towards the
peripheral LED immediately. The central LED was extinguished 500 ms after offset of the
peripheral target and, at this point, the participant was required to make a saccade to the
remembered location of the previously illuminated peripheral LED. In this paradigm, the
buzzer onset that provided the temporal cue, was coincident with the offset of the central
(fixation) LED (see Figure 1 for schematic representation of this paradigm).
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S e Su plementary Materials (S1) for full description of the target configuration and the subject instructions.
2.3. Data Processing and Statistical Analysis
In the memory-guided saccade paradigm, the latency and spatial accuracy or gain
(i.e., saccade eccentricity/target eccentricity) of the initial saccade and the gain of the
final eye position (FEP) on each trial was analysed. The mean and standard deviation of
each parameter was calculated for the four target locations. In the current paradigms, the
Brain Sci. 2021, 11, 1071 6 of 17
number of trials on which a failure of saccadic suppression occurred was tallied for each
participant. In calculating latency and gain, these erroneous responses were discarded. In
assessing saccadic distractibility, an error was registered if a saccade occurred during the
500ms delay between target offset and the imperative cue, buzzer onset (accompanied by
fixation LED offset). For the target eccentricity analyses, the ‘Near’ targets were classified
as those at ±7.5◦ and the ‘Far’ targets were classified as those at ±15◦. ±7.5◦ and ±15◦
were chosen to address previous studies which have used smaller target amplitude (e.g.,
2◦) separations which are ambiguous in whether they are classified as ‘near’ or ‘far’.
3. Results
3.1. Diagnosis-Based Analysis
For the diagnostic-based analyses, participants were separated into M-SZ (n = 29),
NM-SZ (n = 11), M-BD (n = 12), NM-BD (n = 17), and CON (n = 30). To explore the effect of
neuroleptic medication on performance in the memory-guided saccade task, diagnostic
groups (SZ and BD) were collapsed into whether they were neuroleptic medicated (n = 41)
or not on neuroleptic medication (n = 68).
3.1.1. Saccade Primary Saccade Gain
A 2 (target eccentricity: Far, Near) × 5 (Group: M-SZ, NM-SZ, M-BD, NM-BD, CON)
repeated-measures ANOVA was carried out on the primary saccade gain data with Bon-
ferroni post hoc tests for multiple comparisons, where main effects of target eccentricity
(F(1,93) = 8.905, p = 0.004, ηp2 = 0 087) and group (F(4,93) = 4.920, p < 0.001, ηp2 = 0.175) were
found (see Figure 2a). Bonferroni post hoc analyses for multiple comparisons illustrated
how these distinctions were driven by differences between the M-SZ vs. CON (p < 0.001)
and M-SZ vs. NM-BD (p = 0.019) groups (see Figure 2a). Gain control in the M-SZ group
was therefore significantly reduced when contrasted with the NM-BD and CON groups.
To explore the effect of neuroleptic medication, a two (target eccentricity: Far, Near) by
two (medication Status: M, NM) repeated-measures ANOVA was executed, where a main
effect of target eccentricity (F(1,106) = 13.979, p < 0.001, ηp2 = 0.117) and medication status
(F(1,106) = 16.181, p < 0.001, ηp2 = 0.132) was found. This relationship suggests that the
medicated cohort produced significantly lower gain data in both eccentricities compared
to the non-medicated cohort (see Figure 2b).
3.1.2. Saccade Final Eye Position
A two (target eccentricity: Far, Near) by five (group: M-SZ, NM-SZ, M-BD, NM-BD,
CON) repeated-measures ANOVA was performed on the FEP data, where a main effect
of target eccentricity (F(1,93) = 9.253, p = 0.003, ηp2 = 0.090) and group (F(4,93) = 3.065,
p = 0.020, ηp2 = 0.116) were found. Bonferroni post hoc analyses for multiple compar-
isons illustrated how these distinctions were driven by differences between the M-SZ
and NM-BD (p = 0.033) groups (see Figure 2c. FEP in the M-SZ group was, therefore,
significantly reduced when contrasted with the NM-BD group. To explore the effect of
neuroleptic medication, a two (target eccentricity: Far, Near) by two (medication status:
M, NM) repeated-measures ANOVA was carried out. A main effect of target eccentric-
ity (F(1,106) = 16.345, p < 0.001, ηp2 = 0.134) and medication status (F(1,106) = 10.677,
p < 0.001, ηp2 = 0.092) was observed. This relationship suggests that the medicated cohort
displayed greater hypometria in both eccentricities compared to the non-medicated cohort
(see Figure 2d). A target eccentricity*medication status interaction was also found (F(1,106)
= 3.858, p = 0.05, ηp2 = 0.035).
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3.1.3. Saccade Latency
A two (target eccentricity: Far, Near) by five (group: M-SZ, NM-SZ, M-BD, NM-BD,
CON) repeated-measures ANOVA was carried out, where no significant main effects were
observed. To explore the effect of neuroleptic medication, a two (target eccentricity: Far,
Near) by two (medication status: M, NM) repeated-measures ANOVA was executed on
the data. No significant main effects or interactions were observed. This is consistent with
previous research [10,26] revealing that saccade parameter of primary saccade latency is
relatively insensitive to psychosis, neuroleptic r target eccentricity.
In sum, no effects of target e centricity were observed for the latency metric. This is
analogous with the existing liter ture [10,38]. L ndgraf and colleagues [26] highlighted an
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overall group difference in gain control and final eye position; whereby the SZ patients
showed reduced abilities when compared to their family members and controls. The
present research mimics this notion but develops the idea further. Consequently, gain
control and final eye position in the M-SZ patients was significantly diminished in contrast
to the NM-BD and CON groups. Moreover, these measures were lessened further among
targets with greater eccentricities (15◦). This finding was paralleled again when investi-
gating the effect of neuroleptic medication: expectedly, the medicated cohort (regardless
of diagnosis) exhibited reduced gain control and final eye positions in both eccentricities
compared to the non-medicated cohort, but this deficit is markedly observed in the furthest
targets.
3.2. Symptoms-Based Analysis (1)
To establish that collapsing near and far targets from both the left and right literalities
would not add any uncertainties to the data, a two (laterality: left, right) by two (group:
high-SANS, low-SANS) repeated measures ANOVA was explored; illustrating no signifi-
cant effects for latency, gain or FEP in either laterality (p > 0.5). Thus, the analyses include
‘Near’ targets (those at ±7.5◦) and ‘Far’ targets (±15◦).
For the symptom-based analyses, a median split was used to divide the partici-
pants into a high- (score > 18) and low- (score < 18) negative/positive symptoms group.
Initially, groups with high-/low- negative symptoms or high-/low- positive symptoms
were collapsed across diagnosis to explore the singular influence of positive and negative
symptomatology (regardless of diagnostic classification) on memory-guided saccade per-
formance. The constitution of the cohort was as follows: high-SANS (n = 24), low-SANS
(n = 39), high-SAPS (n = 37) and low-SAPS (n = 27).
3.2.1. Primary Saccade Gain
A two (target eccentricity: Far, Near) by two (group: high-SANS, low-SANS) repeated
measures ANOVA was carried out. This analysis highlighted a main effect of target eccen-
tricity (F(1,61) = 7.766, p = 0.007, ηp2 = 0.113; Figure 3a). When looking at the descriptive
statistics, it appears that differences between high- and low-SANS groups are more ap-
parent for the furthest target, but no significant group effect was found. To explore this
potential relationship, a multiple regression was performed to predict group membership
(high vs. low negative groups, collapsed across diagnostic label) from gain control towards
the furthest target and gain control towards the nearest target. These variables did not
significantly predict group membership (F(2,60) = 1.41, p = 0.252, R2 = 0.045). A two (target
eccentricity: Far, Near) by two (group: high-SAPS, low-SAPS) repeated measures ANOVA
was also carried out; displaying a main effect of target eccentricity also (F(1,62) = 7.412,
p = 0.008, ηp2 = 0.107; Figure 3b). For both analyses, gain control displayed greater reduc-
tions towards the furthest target eccentricity. No group differences were observed for either
analysis. A multiple regression was performed to predict group membership (high vs. low
positive groups, collapsed across diagnostic label) from gain control towards the furthest
target and gain control towards the nearest target. These variables did not significantly
predict group membership (F(2,61) = 0.274, p = 0.76, R2 = 0.009).
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3.2.2. Sa cade Final Eye Position
A t (t r et eccentricity: Far, Near) by two (group: high-SANS, low-SAN ) repeated
measures ANOV was carried out. The data reports a main effect of target eccentricity in
FEP (F(1,61) = 11.192, p < 0.001, ηp2 = 0.155; Figure 3), whereby more variability is observed
in the furthest target. To explore this idea, a multiple regression was performed to predict
group membership (high vs. low negative groups, collapsed across diagnostic label) from
FEP towards the furthest target and FEP towards the nearest target. These variables did
not significantly predict group membership (F(2,60) = 1.66, p = 0.199, R2 = 0.052). A two
(target eccentricity: Far, Near) by two (group: high-SAPS, low-SAPS) repeated measures
ANOVA was also executed for the high-/low-SAPS groups; showing a main effect of target
eccentricity in FEP (F(1,62) = 10.048, p = 0.002, ηp2 = 0.139; Figure 3). For both analyses,
FEP showed larger reductions towards the furthest most target. No group differences
were observed for either analysis. A multiple regression was performed to predict group
membership (high vs. low positive groups, collapsed across diagnostic label) from FEP
towards the furthest target and FEP towards the nearest target. These variables did not
significantly predict group membership (F(2,61) = 0.103, p = 0.902, R2 = 0.003).
3.2.3. Saccade Latency
A two (target eccentricity: Far, Near) by two (group: high-SANS, low-SANS) repeated
measures ANOVA was performed; showing no significant effect of the latency metric.
The same analysis (a two (target eccentricity: Far, Near) by two (group: high-SAPS, low-
SAPS) repeated measures ANOVA) was carried out for the high- and low-SAPS groups,
displaying the same result.
3.3. Symptoms-Based An lysis (2)
To investigate the effect of symptomatology between diagnostic categories, a similar
analysis was repeated. Here, participants were grouped based on their high-/low- posi-
tive/negative symptom scores and were then divided by diagnostic category: high-SANS
(SZ n = 13; BD n = 11), low-SANS (SZ n = 11; BD n = 28), high-SAPS (SZ n = 20; BD n = 17),
low-SAPS (SZ n = 11; BD n = 16).
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3.3.1. Primary Saccade Gain
A two (target eccentricity: Far, Near) by four (group: SZ high-SANS, SZ low-SANS,
BD high-SANS, BD low-SANS) repeated measures ANOVA was performed. A significant
effect of target eccentricity was found in the gain metric (F(1,59) = 7.51, p = 0.008, ηp2 = 0.11;
Figure 4c); suggesting reduced gain control for the furthest targets. To explore this potential
relationship a multiple regression was performed to predict group membership (high vs.
low negative groups, divided by diagnostic label) from gain control towards the furthest
target and gain control towards the nearest target. These variables statistically significantly
predicted group membership (F(2,60) = 4.65, p < 0.01, R2 = 0.134). Only gain control
towards the furthest target added statistically significantly to the prediction, p = 0.006. The
equivalent repeated-measures ANOVA was carried out for the SAPS groups; illustrating a
significant effect of target eccentricity (F(1,60) = 8.29, p = 0.006, ηp2 = 0.12; Figure 4d). No
group differences were observed for either analysis. A multiple regression was performed
to predict group membership (high vs. low positive groups, divided by diagnostic label)
from gain control towards the furthest target and gain control towards the nearest target.
These variables statistically significantly predicted group membership (F(2,61) = 3.09,
p = 0.05, R2 = 0.092). Only gain control towards the furthest target added statistically
significantly to the prediction, p = 0.02.
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3.3.2. Saccade Final Eye Position
A two (target eccentricity: Far, Near) by two (group: high-SANS, low-SANS) repeated
a two (target eccentricity: Far, Near) by four (group: SZ high-SANS, SZ low-SANS, BD
high-SANS, BD low-SANS) repeated measures ANOVA was carried out. A significant
effect of target eccentricity was found in the FEP (F(1,59) = 10.72, p = 0.002, ηp2 = 0.15)
metric (Figure 4c); suggesting greater undershooting for the furthest targets. To explore
this target eccentricity relationship further, a multiple regression was performed to predict
group membership (high vs. low negative groups, divided by diagnostic label) from FEP
towards the furthest target and FEP towards the nearest target. These variables statistically
significantly predicted group membership (F(2,60) = 4.06, p = 0.02, R2 = 0.119). Only FEP
towards the furthest target added statistically significantly to the prediction, p = 0.007.
The equivalent repeated-measures ANOVA analysis was executed for the SAPS groups;
illustrating a significant effect of target eccentricity (F(1,60) = 7.89, p = 0.007, ηp2 = 0.116;
Figure 4d). No group differences were observed for either analysis. A multiple regression
was performed to predict group membership (high vs. low positive groups, divided by
diagnostic label) from FEP towards the furthest target and FEP towards the nearest target.
These variables did not statistically significantly predict group membership (F(2,61) = 2.86,
p = 0.06, R2 = 0.086). Only FEP towards the furthest target added statistically significantly
to the prediction, p = 0.026.
3.3.3. Saccade Latency
A two (target eccentricity: Far, Near) by four (group: SZ high-SANS, SZ low-SANS,
BD high-SANS, BD low-SANS) repeated measures ANOVA was carried out; showing no
significant effect of the latency metric. The equivalent analysis was carried out for the SAPS
groups, illustrating no main effects.
3.4. Neuroleptic Medication on Symptomalogy
To explore the effect of neuroleptic medication on symptomatology—when collapsed
across diagnostic category—a two (target eccentricity: Far, Near) by four (group: medicated
high-SANS, medicated low-SANS, non-medicated high-SANS, non-medicated low-SANS)
repeated measures ANOVA was executed and highlighted no significant differences in
the latency metric, but a main effect of target eccentricity in both the gain (F(1,59) = 4.686,
p = 0.034, ηp2 = 0.074) and FEP (F(1,59) = 6.201, p = 0.016, ηp2 = 0.095) measures (see
Figure 5a). A two (target eccentricity: Far, Near) by four (group: medicated high-SAPS,
medicated low-SAPS, non-medicated high-SAPS, non-medicated low-SAPS) repeated
measures ANOVA highlighted no significant differences in the latency metric, but a main
effect of target eccentricity in both the gain (F(1,60) = 6.700, p = 0.012, ηp2 = 0.100) and FEP
(F(1,60) = 9.341, p = 0.003, ηp2 = 0.135) measures (see Figure 5a).
In sum, no symptom-based group or target eccentricity differences were observed
in relation to the latency metric. This aligns with the data reported in the diagnosis-
based analysis. Across analyses exploring the gain control and final eye position metric
no group differences were observed. This highlights a divergence from prior literature
reporting greater deficit among individuals with more negative symptoms in the memory-
guided saccade task [52]. Winograd-Gurvich et al. [52] reported these effects among
percentage of errors; thus, gain control illustrates a distinctly different story. Throughout
the reported symptom-based analyses, however, greater deficit is observed toward the
target with the greatest eccentricity. The analysis investigating the influence of neuroleptic
medication illustrated a clear distinction in gain control and final eye position data between
target eccentricities: with greater hypometric performance observed toward the furthest
eccentricity.
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3.5. Symptomalogy on Error Rates
Crawford et al. [23,44] ported significantly mor errors were exhibited by the
sch zophrenia patients when compared to bipolar affective disorder pati nts and con-
trol participants. Furthermore, Wino ad-Gurvich et al. [52] described h w a igh-negative
symptom group made a significantly greater percentage of errors than controls. Thus, to
explore the influence of symptomatology on error rate production, groups were collapsed
into high-SANS (n = 36) and low-SANS (n = 38) categories, regardless of diagnostic category.
This was also true for high-SAPS (n = 37) and low-SAPS (n = 38). When investigated in this
manner, the high-SANS group were shown to produce significantly more errors than the
low-SANS (F(1,72) = 4.93, p = 0.03), but this was not true of the high-/low- SAPS groups
(F(1,73) = 0.55, p = 0.46; Figure 6b). See the Supplementary Table S2 for all descriptive statis-
tics. This provides support for previous literature [52,53], fostering further the notion that
psychotic saccadic deficits may be driv n by those individuals experiencing predominantly
negative symptoms.
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As per the symptom-based analyses reported beforehand, the diagnostic groups
were also divided using a median-split into those with high and low negative/positive
symptoms: SZ high-SANS (n = 17), SZ low-SANS (n = 12), BD high-SANS (n = 14), BD
low-SANS (n = 31), SZ high-SAPS (n = 26), SZ low-SAPS (n = 19), BD high-SAPS (n = 8),
BD low-SAPS (n = 22). Under these conditions, error production was found to differ
significantly between the groups (F(3,70) = 3.13, p = 0.03; Figure 6a), whereby significantly
more errors were produced by the SZ high–SANS cohort compared to the BD low-SANS
cohort (p = 0.03). No significant differences were found for the same analysis with high-
and low- SAPS (F(3,71) = 2.27, p = 0.09).
4. Discussion
To our knowledge, this is the first study of memory-guided saccades to explore target
eccentricity in relation to psychosis diagnosis, psychotic symptomatology and the effect of
medication. In a recent paper, greater errors were produced by SZ patients [43] in response
to further targets (12◦), when compared to near target (6◦), although no exploration was
given toward the breakdown of symptomatology in this patient group. The present
research, therefore, expanded this finding to explore the effect of target eccentricity across
diagnostic groups, and between symptom-types. The importance of eccentricity in saccade
paradigms relates to the mammalian cortical magnification factor. The representation of
retinal ganglion cells is disproportionately increased for foveal compared to peripheral
retinal cells and proportional to the distance from the foveal region. Thus, the projections
and resolution from 15◦ will be substantially reduced compared to 7.5◦. Therefore, 15◦
activation is likely to be generate a weaker cortical representation, and therefore, potentially
more vulnerability to the psychopathology of psychosis. Moreover, larger saccades require
greater energy expenditure, with larger neural pulse-steps to generate increased peak
velocity and saccade duration for larger saccades. This increased energy demand may
make larger saccades, and in the context of the present research, memory representation,
more vulnerable to psychopathology.
The current analyses focused on two questions, (1) how do psychotic disorders
(schizophrenia and bipolar affective disorder) respond when presented with targets of
differing eccentricity in the memory-guided saccade task, and how does medication influ-
ence this performance, and (2) how do patients experiencing predominantly negative or
predominantly positive symptoms perform?
Data demonstrated no significant group differences when utilising the latency metric;
replicating the existing research carried out by Schwartz et al. [42] and Landgraf et al. [26].
With regards to gain control and final eye position, group differences became apparent,
highlighting greater deficit among medicated schizophrenia patients and a generally larger
impairment towards the furthest target. This finding contrasts the existing literature,
whereby deficits in gain control were reported to be prominent among patients with a
family history of schizophrenia at smaller angles [42]. However, Schwartz and colleagues
found reduced gain at smaller angles (5◦–10◦) in those patients with a family history of
schizophrenia, whereas, at larger angles (16◦–30◦) both patients with and without a family
history of schizophrenia exhibited reduced gain control compared to controls. Thus, the
present research is consistent with the relationship shown by Schwartz et al. [42] at the far
targets. This is also supported by a recent study by Norouzi et al. [43] who highlighted,
among a neurotypical sample, that greater quantities of errors are made toward a target
with a greater eccentricity (12◦).
Similarly, in relation to symptomatology, greater hypometria and reduced gain control
was observed toward the furthest targets. Throughout the symptom-based analyses, greater
deficit is observed toward the target with the greatest eccentricity; although, although no
group differences were reported throughout the symptom-based analyses. To explore the
idea that the far target may be the better predictor of deficit among these participant groups,
multiple regressions showed that when exploring symptomatology (divided by diagnostic
category, i.e., SZ high-SANS vs. BD high SANS), only the furthest targets significantly
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accounted for unique group variance in both the eccentricity gain and FEP measures. This,
however, was only true when diagnostic category was used to divide the symptom-based
groups. When high-/low- SANS groups were collapsed across diagnoses, these significant
predictions withdrew. The analysis investigating the influence of medication illustrated a
clear distinction in gain control and final eye position data between target eccentricities:
with greater hypometric performance observed toward the furthest eccentricity and greater
deficit for those medicated patients.
In addition to the saccade metrics reported, the present research also explored error
production between groups and symptomatology. A series of studies [52–54] reported that
greater saccade deficit was observed among individuals who presented with predominantly
negative symptoms. Specifically, a greater proportion of errors have been reported among
those with high-negative symptoms [52]; prompting the investigation of error production
among the current patient cohort. When symptomatology was explored by collapsing
all diagnostic categories into predominantly high/low negative/positive symptoms, the
high-SANS group were shown to produce significantly more errors than the low-SANS,
supporting existing hypotheses. Further, when symptomatology was explored considering
diagnostic criteria as well, significantly more errors were produced by the SZ high-SANS
cohort and the BD high-SANS cohort in comparison to their corresponding low-SANS
cohorts. No such relationship was found for the comparative positive symptoms. This
strengthens the notion that saccade deficits, on this occasion, error production, are driven
by negative symptoms.
Strengths and Limitations
The present research aimed to provide an update on the existing understanding of
the memory-guided saccade paradigm, taking into account the methodological limitations
in the previous literature. To extend our understanding of memory-guided saccade per-
formance among psychosis patients, we included three measures of oculomotor abilities—
latency, gain control, and final eye position—to provide a more comprehensive insight into
the relationship of psychotic symptoms and target eccentricity. The present data supports
the view that gain control and final eye position are promising predictors of psychosis
severity; a notion supported by the lack of main effects observed for the latency measure
throughout analyses. Moreover, the present data also argues that when investigating
degree of deficit among psychosis-spectrum diagnoses, the inclusion of distance target
eccentricities (at least 15◦) is important, and that reliance on near target eccentricities will
risk a loss in sensitivity. Indeed, when resources are limited, it will be a more efficient
approach to include only the furthest targets as they provide a sensitive predictor of clinical
impairment.
All of the schizophrenia patients who partook in the research reported by Schwartz
et al. [42] and Landgraf et al. [26] were medicated; thus, we sought to explore whether
differences in memory-guided saccade performance would occur as a consequence of
neuroleptic medication status. The data revealed that the medicated groups (with reference
to both diagnostic classification and symptomatology-based analyses) performed with
heightened deficit in both gain control and final eye position metrics. This, as far as we
are aware, is the only research to explore the influence of medication on memory-guided
saccade performance in relation to target eccentricity. Moreover, to extend the investigation
reported by Winograd-Gurvich et al. [52], the current research also explored the effect
of target eccentricity on symptomatology. Winograd-Gurvich et al. [52] reported (with
reference to target laterality) that among a cohort of medicated schizophrenia patients,
divided by their experience of negative symptoms (high vs. low), no group differences
were reported for gain control or final eye position when comparing the high vs. low
symptom groups with controls. This finding was replicated in the present dataset with
reference to target eccentricity: no group difference with respect to symptomatology were
reported. This suggests that within the memory-guided saccade paradigm, diagnostic
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classification is more prominent in distinguishing differences in saccade performance than
symptomatology.
As well as strengths to the present research, there are also limitations worth noting
so they can be addressed when moving forward into future memory-guided saccade
explorations. Landgraf et al. [26] reported a reduction in error production between small
eccentricities and larger eccentricities, which was not present among patients; the present
research displayed analyses exploring overall error production amongst symptom-groups,
but dividing the errors between target eccentricities was an analysis we were not able
to explore in relation to symptomatology. As the present research relied on secondary
data analyses it was not possible to explore errors produced toward near and far targets,
but this should be considered a priori in future work. Another constraint on the present
research were the differential sized cohorts; the absence of a sample size calculation for
the different groups used throughout the series of hypothesis-driven analyses, makes the
evaluation of statistical power adequacy difficult. This was highlighted particularly during
the symptom-based analyses, where we explored symptomatology—predominantly high-
/low-SANS and high-/low-SAPS—within the diagnostic classifications. To combat the
cohort imbalance, we reported the above analyses and also collapsed high SANS and low
SANS groups across diagnosis to explore the singular influence of positive and negative
symptomatology (regardless of diagnostic classification).
5. Conclusions
The present research extends our understanding of deficit displayed in the memory-
guided saccade task and the influence target eccentricity has on psychotic performance.
This study reveals that a greater target eccentricity discriminates better between psychiatric
groups, particularly for gain control and final eye position metrics. Extensive research in
the last 20 years has substantially advanced our understanding of the essential features for
the development of oculomotor biomarkers required for the early diagnosis of psychosis.
The current findings build on this work by revealing the importance detailed parameter
measurement to optimize the sensitivity of these paradigms.
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